PharmaVentures Advises Transgene on the Sale of Their Biopharmaceutical Manufacturing Plant

OXFORD, England, February 4, 2016 /PRNewswire/ --

PharmaVentures is pleased to announce that it acted as an advisor to Transgene on the sale of its biopharmaceutical manufacturing unit in Strasbourg, France, to the US company Advanced Bioscience Laboratories (ABL), Inc.

Transgene (Euronext: TNG), a member of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases.

ABL, also a member of Institut Mérieux, is a leading US contract research and manufacturing organisation. The Strasbourg acquisition will enable the company to establish ABL Europe and to increase its capabilities as a contract manufacturer with a stronger foothold within European Union.

Nigel Borshell, Vice President of PharmaVentures said: "We are delighted to have helped Transgene find a buyer for their biopharmaceutical manufacturing facility and to see its continued operation by ABL as a strategic and high value asset".

Fintan Walton, Chief Executive of PharmaVentures said: "Yet again the successful sale of this manufacturing facility in France shows that PharmaVentures is a leader in finding buyers for pharmaceutical companies wishing to divest assets."

For over 23 years, PharmaVentures has acted as advisor to over 700 pharmaceutical and biotechnology clients in transactions; covering licensing, mergers, acquisitions, divestments and joint venture activities for companies.

About PharmaVentures, Ltd

PharmaVentures is a premier transaction advisory firm; a leader in partnering, M&A deals and strategic alliances. 

An unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes them uniquely placed to support your business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

Find out more http://www.pharmaventures.com

Their services include: 

• M&A (divestments, mergers, acquisitions and strategic transactions)
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuation and Positioning (licensing, M&A, fund raising & expert testimonies)
• Licensing (in and out licensing)
• Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)

Now in its 24th year, PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in N. America, Latin America, and Asia-Pacific.